Shares of Cybin Inc., now operating as Helus Pharma, jumped 10.7% to $11.17 on August 12 as investors piled in ahead of the company's fiscal second-quarter earnings report and a same-day fireside chat with CEO Michael Halstead at the Canaccord Genuity conference. The rally reflects a classic biotech gamble: a clinical-stage company burning cash fast, generating zero revenue, and asking shareholders to bet entirely on the outcome of a late-stage depression drug trial.
• The Earnings Report Won't Show Revenue — Investors Are Buying the Story, Not the Numbers. Analysts expect a GAAP EPS loss of roughly -$0.82 on $0 in revenue . Last quarter, Cybin posted a loss of -$31.1 million** . The stock is moving not on financials but on what management may disclose about the progress of its lead drug candidate — a modified psilocybin-based therapy in a Phase 3 trial for major depressive disorder. Today's Canaccord appearance could provide fresh details on trial timelines.
• The Depression Drug Trial Is Nearing the Finish Line — And That's the Whole Thesis. The company's APPROACH Phase 3 trial has surpassed 86% enrollment, keeping it on track for a topline data readout in Q4 2026 . Earlier Phase 2 results were striking: response and remission rates hit 75% at week 18, climbing to 100% and 71% respectively at 12 months . The drug has also received Breakthrough Therapy Designation from the FDA , which can speed regulatory review. If Phase 3 replicates those numbers, it's a potential blockbuster. If it doesn't, the stock has very little underneath it.
• Cash Is Dwindling Faster Than It Arrives. After a $50 million equity raise in June 2026, Cybin holds about $242 million with no debt, giving it roughly 1.9 years of runway . But annual cash burn of $114 million represents about 53% of the company's market capitalization — an extraordinary ratio that virtually guarantees more share dilution if timelines slip.
• Analyst Targets Are Sky-High, But the Gap Signals Extreme Uncertainty. Wall Street's average price target sits at $34, with a range spanning from $8 to $70 . HC Wainwright recently lowered its target from $95 to $70 while maintaining a Buy rating . That enormous spread tells you everything: this is a binary outcome stock. The Q4 data readout will either validate or demolish the investment case. Until then, every rally is borrowed conviction.